<DOC>
	<DOCNO>NCT00014625</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness E7070 treat patient stage IV melanoma .</brief_summary>
	<brief_title>E7070 Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine therapeutic activity E7070 term objective response , duration response , progression-free survival patient metastatic melanoma . II . Determine acute side effect drug patient . III . Determine pharmacokinetic parameter drug patient . OUTLINE : This multicenter study . Patients receive E7070 IV 1 hour . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients follow every 6 week . PROJECTED ACCRUAL : A total 19-24 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV melanoma Metastatic disease At least 1 bidimensionally measurable target lesion CT scan No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR WHO 02 Life expectancy : Not specify Hematopoietic : Hemoglobin great 10 g/dL Neutrophil count great 2,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN ( 5 time ULN liver metastasis present ) Transaminases great 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.7 mg/dL Cardiovascular : Clinically normal cardiac function No history severe unstable ischemic heart disease 12lead ECG normal Other : No history unstable systemic disease No concurrent uncontrolled diabetes mellitus No concurrent infection No history hypersensitivity sulfonamides No malignancy within past 5 year except conebiopsied carcinoma cervix adequately treat basal cell squamous cell skin cancer No psychological , familial , sociological , geographical condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior blood transfusion At least 2 week since prior growth factor At least 6 week since prior experimental vaccine therapy No prior immunotherapy metastatic disease No concurrent anticancer immunotherapy Chemotherapy : No prior chemotherapy metastatic disease No concurrent anticancer chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : No concurrent anticancer radiotherapy except palliation pain control reason ( e.g. , bronchial obstruction ulcerate skin lesion ) curative intent Surgery : Not specify Other : At least 6 week since prior adjuvant neoadjuvant therapy At least 4 week since prior experimental drug At least 2 week since prior concurrent coumarin anticoagulant , terfenadine , cisapride , cyclosporine , tacrolimus , theophylline , diazepam , sulfonylurea antidiabetic , phenytoin , carbamazepine No concurrent experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>